Article ; Online: High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib.
2021 Volume 35, Issue 2, Page(s) 485–493
Abstract: ... analysis. In conclusion, we found a high risk of mortality during COVID-19 infection among MPN patients ... with myeloproliferative neoplasms (MPN) and COVID-19, diagnosed between February and June 2020. After a median follow-up ... especially in MF patients and/or discontinuing Ruxo at COVID-19 diagnosis. These findings call for deeper ...
| Abstract | We report the clinical presentation and risk factors for survival in 175 patients with myeloproliferative neoplasms (MPN) and COVID-19, diagnosed between February and June 2020. After a median follow-up of 50 days, mortality was higher than in the general population and reached 48% in myelofibrosis (MF). Univariate analysis, showed a significant relationship between death and age, male gender, decreased lymphocyte counts, need for respiratory support, comorbidities and diagnosis of MF, while no association with essential thrombocythemia (ET), polycythemia vera (PV), and prefibrotic-PMF (pre-PMF) was found. Regarding MPN-directed therapy ongoing at the time of COVID-19 diagnosis, Ruxolitinib (Ruxo) was significantly more frequent in patients who died in comparison with survivors (p = 0.006). Conversely, multivariable analysis found no effect of Ruxo alone on mortality, but highlighted an increased risk of death in the 11 out of 45 patients who discontinued treatment. These findings were also confirmed in a propensity score matching analysis. In conclusion, we found a high risk of mortality during COVID-19 infection among MPN patients, especially in MF patients and/or discontinuing Ruxo at COVID-19 diagnosis. These findings call for deeper investigation on the role of Ruxo treatment and its interruption, in affecting mortality in MPN patients with COVID-19. |
|||||
|---|---|---|---|---|---|---|
| MeSH term(s) | Aged ; COVID-19/complications ; COVID-19/mortality ; COVID-19/transmission ; COVID-19/virology ; Europe/epidemiology ; Female ; Follow-Up Studies ; Humans ; Male ; Middle Aged ; Myeloproliferative Disorders/drug therapy ; Myeloproliferative Disorders/epidemiology ; Myeloproliferative Disorders/mortality ; Myeloproliferative Disorders/virology ; Prognosis ; Pyrazoles/administration & dosage ; Retrospective Studies ; SARS-CoV-2/isolation & purification ; Survival Rate ; Withholding Treatment/statistics & numerical data | |||||
| Chemical Substances | Pyrazoles ; ruxolitinib (82S8X8XX8H) | |||||
| Language | English | |||||
| Publishing date | 2021-01-07 | |||||
| Publishing country | England | |||||
| Document type | Journal Article ; Multicenter Study ; Research Support, Non-U.S. Gov't | |||||
| ZDB-ID | 807030-1 | |||||
| ISSN | 1476-5551 ; 0887-6924 | |||||
| ISSN (online) | 1476-5551 | |||||
| ISSN | 0887-6924 | |||||
| DOI | 10.1038/s41375-020-01107-y | |||||
| Shelf mark |
|
|||||
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
Full text online
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
| Zs.A 2295: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.